节点文献
静脉注射免疫球蛋白治疗儿童川崎病的循证指南（2023）
Evidence-based guideline for intravenous immunoglobulin treatment of Kawasaki disease in children(2023)
【摘要】 川崎病（KD）在中国发病率逐年增高，静脉注射免疫球蛋白（IVIG）是KD的一线治疗方案。目前关于KD的指南多侧重于临床诊断，IVIG治疗KD的指南缺乏多学科循证证据支持。本指南遵循《世界卫生组织指南制订手册》和《中国制订/修订临床诊疗指南的指导原则（2022版）》，通过问卷调研儿科医师和临床药师，确定10个临床问题。基于国内外现有证据，同时考虑中国患者的偏好与价值观、干预措施的成本、利弊和可及性等因素，通过德尔菲法调研，最终形成关于IVIG治疗儿童KD的10条推荐意见。本指南适用于各级医院从事KD相关工作的临床医师和临床药师。
【Abstract】 The incidence of Kawasaki disease(KD) has increased in China, and intravenous immunoglobulin(IVIG) is a first-line treatment for KD. Current guidelines on KD mostly focus on its diagnosis, while guidelines on IVIG for KD still lack evidence support. This guideline refers to the World Health Organisation Handbook for Guideline Development and Guidelines for the Development/Revision of Clinical Practice Guidelines in China(2022 edition). In this study a questionnaire was administered to pediatricians and clinical pharmacists to identify 10 clinical questions. Ten recommendations on IVIG for KD in children were finalized through Delphi based on available evidence, as well as the values of patient preferences, the cost, the balance of pros and cons, and accessibility of interventions. The guideline is applicable to clinicians and pharmacists working on KD in all levels of hospitals.
【Key words】 pediatric； Kawasaki disease； intravenous immunoglobulin； evidence-based guideline；
- 【文献出处】 兰州大学学报(医学版) ,Journal of Lanzhou University(Medical Sciences) , 编辑部邮箱 ,2024年01期
- 【分类号】R725.4
- 【下载频次】131